Condition: Recurrent Triple-Negative Breast Cancer · Sponsor: Yukinori Ozaki
* Breast cancer is histologically divided into non-invasive (approximately 10%) and invasive (approximately 90%), with invasive cancer being the target of chemotherapy. Invasive carcinoma is classified into four subtypes according to the expression levels of hormone receptor (HR) and human epidermal growth factor receptor type 2 (HER2). Among them, triple negative breast cancer accounts for 10% of invasive cancers and is the subtype with the poorest prognosis. * For triple negative breast cancer that is operable, chemotherapy with pembrolizumab is administered either preoperatively or postoperatively (perioperative period). For recurrent triple negative breast cancer , combination chemotherapy with multiple agents is the standard of care, especially in the case of PD-L1-positive patients, chemotherapy with an immune checkpoint inhibitor related to PD-1 (pembrolizumab or atezolizumab) is administered. * Although the KEYNOTE355 trial demonstrated the efficacy of pembrolizumab plus paclitaxel therapy in patients with PD-L1-positive triple negative breast cancer in postoperative relapse, this trial did not include patients who received pembrolizumab in the perioperative period. Therefore, it is not known if there is any benefit to re-administering pembrolizumab to these patients after relapse. * Bevacizumab is used as standard therapy for triple negative breast cancer in combination with paclitaxel. Bevacizumab itself is an anti-tumor agent that inhibits angiogenesis, but has als…
This description comes directly from the study's public registry record.
Yukinori Ozaki · +81-3-3520-0111 · yukinori.ozaki@jfcr.or.jp
Kazuki Nozawa · +81-52-851-5511 · k.nozawa@med.nagoya-cu.ac.jp
Always discuss trial participation with your own doctor first.
| National Hospital Organization Nagoya Medical Center | Nagoya, Aichi-ken, Japan | Recruiting |
| Nagoya University Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| Nagoya City University Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| National Cancer Center Hospital East | Kashiwa-shi, Chiba, Japan | Recruiting |
| Gifu University Hospital | Gifu, Gifu, Japan | Recruiting |
| Hiroshima University Hospital | Hiroshima, Hiroshima, Japan | Recruiting |
| Hokkaido University Hospital | Sapporo, Hokkaido, Japan | Recruiting |
| Hyogo Cancer Center | Akashi-shi, Hyōgo, Japan | Recruiting |
| Okayama University Hospital | Okayama, Okayama-ken, Japan | Recruiting |
| Osaka International Cancer Institute | Osaka, Osaka, Japan | Recruiting |
| Osaka Metropolitan University Hospital | Osaka, Osaka, Japan | Recruiting |
| Kindai University Hospital | Sakai-shi, Osaka, Japan | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06976944